Stately Bio is a biotechnology company headquartered in Palo Alto, California, founded in 2022 by Frank Li. The company specializes in developing regenerative medicines using a machine learning-based cell imaging platform. This technology enables the analysis of live cells without the need for labels or dyes, preserving cell viability and providing insights into cell identity, behavior, and maturation.

Stately Bio's approach allows for real-time, label-free imaging of living cells, facilitating the discovery of novel stem cell-derived therapies. The company collaborates with leading institutions, such as the New York Blood Center, to advance cell therapy innovation.